Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHA 136 in Healthy Subjects
NCT04036656Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of SYHA136 in venous thrombosis (8 cohorts), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Adverse Events at 12 Days, Serious Adverse Events at 12 Days and 3 more. Status: unknown.
02
Drugs
SYHA136
03
Conditions
venous thrombosis
Beyond the preview
Go deeper on NCT04036656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036656.